These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16423478)

  • 1. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors.
    Molina-Trinidad EM; de Murphy CA; Ferro-Flores G; Murphy-Stack E; Jung-Cook H
    Int J Pharm; 2006 Mar; 310(1-2):125-30. PubMed ID: 16423478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats.
    Molina-Trinidad EM; de Murphy CA; Jung-Cook H; Stack EM; Pedraza-Lopez M; Morales-Marquez JL; Serrano GV
    J Pharm Pharmacol; 2010 Apr; 62(4):456-61. PubMed ID: 20604834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
    Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
    J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of (188)Re-beta-naphthyl-peptide in cervical carcinoma tumours in athymic mice.
    Arteaga de Murphy C; Pedraza-López M; Ferro-Flores G; Murphy-Stack E; Chávez-Mercado L; Ascencio JA; García-Salinas L; Hernández-Gutiérrez S
    Nucl Med Biol; 2001 Apr; 28(3):319-26. PubMed ID: 11323244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Labeling and quality control of 188Re-lanreotide.
    Verdera S; Balter H; Rodríguez G; Oliver P; Souto B; López A; Goncalvez Z
    Cell Mol Biol (Noisy-le-grand); 2002 Nov; 48(7):741-5. PubMed ID: 12619968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanreotide labeled with 99mTc: preparation, preclinical testing and comparison with (111)In-DTPA-octreotide.
    Laznicek M; Laznickova A; Trejtnar F; Lorenc P; Varvarigou A; Bouziotis P; Archimandritis S
    Anticancer Res; 2002; 22(4):2125-30. PubMed ID: 12174893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
    Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
    Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of the 188Re(V)-DMSA complex by cervical carcinoma cells in nude mice: pharmacokinetics and dosimetry.
    García-Salinas L; Ferro-Flores G; Arteaga-Murphy C; Pedraza-López M; Hernández-Gutiérrez S; Azorin-Nieto J
    Appl Radiat Isot; 2001 Mar; 54(3):413-8. PubMed ID: 11214875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.
    Nelson CA; Azure MT; Adams CT; Zinn KR
    J Nucl Med; 2014 Dec; 55(12):2020-5. PubMed ID: 25359879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C; Schubiger PA; Schibli R
    Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re.
    Zinn KR; Buchsbaum DJ; Chaudhuri TR; Mountz JM; Grizzle WE; Rogers BE
    J Nucl Med; 2000 May; 41(5):887-95. PubMed ID: 10809205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer.
    Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Schmitt J; Forssel-Aronsson E
    Cancer Biother Radiopharm; 2003 Aug; 18(4):593-9. PubMed ID: 14503955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trends in peptide receptor radioligands.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Andreae F; Kurtaran A; Dudczak R
    Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
    Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
    J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.